内蒙古大学王建国团队报道了用于癌症光疗的高稳定近红外发光二自由基化合物。相关研究成果于2024年11月13日发表在国际知名学术期刊《美国化学会杂志》。

近红外II（NIR-II）光疗剂已成为癌症早期诊断和精确治疗的重要药物。具有独特结构和窄带隙的有机开壳二自由基类化合物，因其强烈的自旋耦合效应和近红外光捕获能力，而成为光疗剂的有前景的候选者。然而，考虑到其高化学反应性和自吸收性，实现稳定有效的NIR-II发光二自由基类化合物至关重要，但也颇具挑战性。

该文中，研究人员通过采用受主平面化/π共轭扩展和施主旋转策略，成功制备了两种高度稳定的NIR-II发光二自由基化合物2PhNVDPP和PhNVDPP。

在包封到水分散性纳米粒子（NPs）中后，2PhNVDPP NPs表现出NIR-II发光、53%的高PCE和改进的光/热稳定性。2PhNVDPP NPs的体内实验证明了血管和肿瘤的清晰可视化，以及成功的NIR-II成像引导的肿瘤光热消融。

该项研究不仅开发了一种具有NIR-II发光的开创性稳定的二自由基类光疗剂，还为多模式抗癌治疗的有效性提供了独特的视角。

附：英文原文

Title: Highly Stable Near-Infrared II Luminescent Diradicaloids for Cancer Phototheranostics

Author: Lina Feng, Yanyan Tuo, Zipeng Wu, Weijing Zhang, Chunbin Li, Bo Yang, Lingxiu Liu, Jianye Gong, Guoyu Jiang, Wei Hu, Ben Zhong Tang, Limin Wu, Jianguo Wang

Issue&Volume: November 13, 2024

Abstract: Near-infrared II (NIR-II) phototheranostic agents have become prominent agents for the early diagnosis and precise treatment of cancer. Organic open-shell diradicaloids with distinct structure and narrow band gap are promising candidates for phototherapeutic agents due to their strong spin-coupling effect and NIR light-harvesting capacity. However, achieving stable and efficient NIR-II luminescent diradicaloids is crucial yet rather challenging considering their high chemical reactivity and self-absorption. Herein, two highly stable NIR-II luminescent diradicaloids, 2PhNVDPP and PhNVDPP, were successfully fabricated by employing an acceptor planarization/π-conjugation extension and donor rotation strategy. After encapsulation into water-dispersible nanoparticles (NPs), 2PhNVDPP NPs exhibit NIR-II luminescence, high PCE of 53%, and improved photo/heat stability. In vivo experiments with 2PhNVDPP NPs demonstrated the clear visualization of blood vessels and tumors, as well as the successful NIR-II imaging-guided photothermal ablation of tumors. This study not only develops a pioneering stable diradicaloid phototherapeutic agent with NIR-II luminescence but also provides a unique perspective for the effectiveness of multimodal anticancer therapy.

DOI: 10.1021/jacs.4c11549

Source: https://pubs.acs.org/doi/abs/10.1021/jacs.4c11549